Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis.

Background: Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. Little real-world evidence is available regarding the effects of tildrakizumab on patients' health-related quality of life (HRQoL) and patient-reported symptoms.Objective: This real-world study of tildrakizumab evaluated changes in HRQoL and clinical symptoms in patients with psoriasis.Materials and methods: In this Week (W)28 interim analysis of a 64-week Phase 4 study (NCT03718299), patients received tildrakizumab 100 mg at W0, W4, and every 12 weeks thereafter. Endpoints were improvement from baseline in Psychological General Well-Being Index (PGWBI), Dermatology Life Quality Index (DLQI), and Itch-, Pain-, and Scaling-Numerical Rating Scale scores through W28.Results: Of 55 patients enrolled, 53 were assessed at W28. Mean (standard deviation [SD]) total PGWBI score improved from baseline to W28 (change, 3.7 [12.4]; P = .033), as did the positive well-being (1.0 [2.9]; P = .018) and general health (1.5 [2.2]; P <.001) domain scores. Mean (SD) DLQI score improved by -3.9 (4.3) at W4 and by -7.6 (5.1) at W28 (P <.001). Patient-reported symptoms improved starting at W4 (P <.001).Conclusion: Tildrakizumab treatment improved HRQoL and patient-reported symptoms in patients with psoriasis in a real-world setting.

[1]  M. Honma,et al.  Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study , 2022, JAAD international.

[2]  I. Flisiak,et al.  Assessment of Life Quality, Stress and Physical Activity Among Patients with Psoriasis , 2021, Dermatology and Therapy.

[3]  B. Elewski,et al.  The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis , 2021, Journal of the American Academy of Dermatology.

[4]  Shunping Li,et al.  Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study , 2020, Health and Quality of Life Outcomes.

[5]  E. H. Thompson,et al.  Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis , 2020, JAMA dermatology.

[6]  H. Miot,et al.  Quality of life of patients living with psoriasis: a qualitative study , 2020, BMC Dermatology.

[7]  G. Pellacani,et al.  Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL) , 2020, Dermatology and Therapy.

[8]  K. Reich,et al.  Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials , 2020, The Journal of dermatological treatment.

[9]  M. Biermann,et al.  Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life , 2020, The Journal of dermatological treatment.

[10]  M. Gooderham,et al.  Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  B. Strober,et al.  Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry , 2019, BMJ Open.

[12]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[13]  A. Kimball,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.

[14]  H. Thom,et al.  Clear or almost clear skin improves the quality of life in patients with moderate‐to‐severe psoriasis: a systematic review and meta‐analysis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  H. Nakagawa,et al.  Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. , 2016, Journal of dermatological science.

[16]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[17]  D. Revicki,et al.  Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis , 2015, The Journal of dermatological treatment.

[18]  J. Koo,et al.  A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. , 2013, Journal of the American Academy of Dermatology.

[19]  M. Bayliss,et al.  The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups , 2009, Health and quality of life outcomes.

[20]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[21]  M. Sprangers,et al.  Quality of life in patients with psoriasis: a systematic literature review. , 2004, The journal of investigative dermatology. Symposium proceedings.

[22]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.